Amikacin

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Amikacin

---

CLASS

Aminoglycoside

---

TARGET PROTEIN

formyl-methionyl-tRNA

---

MECHANISM OF ACTION

Bactericidal activity (It is a protein synthesis inhibitor that hinders binding of formyl-methionyl-tRNA to the bacterial ribosomal 30S subunit)

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Experimental

---

MODE OF ADMINISTRATION

Injectable

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/32091697/                                                                                   

https://pubmed.ncbi.nlm.nih.gov/14659652/

---

SIMILAR TARGETS IN OTHER SPECIES

30S ribosomal protein S12 ~ Escherichia coli (strain K12)

---

DRUG BANK ID

DB00479

---

EXTERNAL LINKS

Human Metabolome Database HMDB0014622

KEGG Drug D02543

KEGG Compound C06820

PubChem Compound 37768

PubChem Substance 46506386

ChemSpider 34635

BindingDB 50237603

RxNav 641


ChEBI 2637


ChEMBL CHEMBL177

ZINC ZINC000008214483

Drugs.com  Drugs.com Drug Page  https://www.drugs.com/cdi/amikacin.html

Wikipedia Amikacin

---

REFERENCE

Wu, A., March, L., Zheng, X., Huang, J., Wang, X., Zhao, J., M.Blyth, F., Smith, E., Buchbinder, R., & Hoy, D. (2020). Enhanced Reader.pdf. In Nature (Vol. 388, pp. 1–14).



Pluschke, G., & Röltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4

---